According to the American Diabetes Association (ADA), recommended therapy for T2DM consists of matching the prandial insulin dose to premeal blood glucose, carbohydrate intake, and anticipated activity.1 For many patients (especially if hypoglycemia is a problem), use of insulin analogs is recommended.2 The use of rapid-acting insulin analogs, such as insulin lispro, insulin aspart, or insulin glulisine, also facilitates flexible dosing in these insulin treatment regimens. The gene discussed is INS; the disease is diabetes mellitus.